Merck, Inc.
🇺🇸United States
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003)
Phase 3
Completed
- Conditions
- Genital WartsAnal CancerAnal Intraepithelial Neoplasia
- Interventions
- Biological: 9vHPV Vaccine
- First Posted Date
- 2012-07-27
- Last Posted Date
- 2018-11-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 2520
- Registration Number
- NCT01651949
A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974)
Phase 1
Completed
- Conditions
- Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
- Interventions
- Biological: Rituximab
- First Posted Date
- 2012-07-26
- Last Posted Date
- 2015-02-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 5
- Registration Number
- NCT01650727
Safety and Tolerability of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin for the Treatment of Vietnamese Subjects With Chronic Hepatitis C Genotype 1 (P08599)
Phase 3
Withdrawn
- Conditions
- Chronic Hepatitis C
- Interventions
- First Posted Date
- 2012-07-17
- Last Posted Date
- 2015-09-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Registration Number
- NCT01641666
A Study of the Safety and Efficacy of Pegylated Inferferon Alfa-2b (PEG-Intron™) Versus Pegylated Interferon Alfa-2a (PEGASYS™) in Participants With Chronic Hepatitis B (P08450)
Phase 3
Terminated
- Conditions
- Hepatitis B, Chronic
- Interventions
- Biological: PEG-Intron™Biological: PEGASYS™
- First Posted Date
- 2012-07-17
- Last Posted Date
- 2018-08-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 402
- Registration Number
- NCT01641926
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8655 in Participants With Type 2 Diabetes (MK-8655-002)
- First Posted Date
- 2012-07-16
- Last Posted Date
- 2018-11-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 33
- Registration Number
- NCT01640873
A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC)
Phase 4
Completed
- Conditions
- VomitingNausea
- Interventions
- First Posted Date
- 2012-07-10
- Last Posted Date
- 2018-09-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 494
- Registration Number
- NCT01636947
A Study of Pegylated Interferon Alfa-2b (MK-4031) as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma (MK-4031-370)
Phase 1
Terminated
- Conditions
- Malignant Melanoma
- Interventions
- Biological: PegIFN alfa-2b
- First Posted Date
- 2012-07-10
- Last Posted Date
- 2018-08-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 9
- Registration Number
- NCT01636960
A Dose-Ranging Study to Compare Doravirine (MK-1439) Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
Phase 2
Completed
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2012-07-02
- Last Posted Date
- 2019-07-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 342
- Registration Number
- NCT01632345
A Study of Odanacatib When Administered to Adolescents and Young Adults Treated With Glucocorticoids (MK-0822-066)
- First Posted Date
- 2012-06-28
- Last Posted Date
- 2018-08-28
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 19
- Registration Number
- NCT01630616
A Single Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Participants With Renal Insufficiency (MK-4618-014)
- First Posted Date
- 2012-06-26
- Last Posted Date
- 2018-12-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 32
- Registration Number
- NCT01628042